Prescription-only, Bluetooth-connected home peak-flow/spirometry monitor with symptom-and-medication tracking for pediatric persistent asthma, billed under the RPM CPT code family
8/9
factors scored
4/4
core factors
14/40
claims verified
0
refuted
How to read a tag. Only
verified counts toward a score — it means a typed connector
resolved this against a primary US federal record.
unconfirmed means the Verifier checked and could not confirm,
which very often means the source could not be queried at all rather than that
the claim is doubtful. refuted means a primary source
contradicts it. unverified means nothing has checked it yet.
claim 1verifiedUS
The "Asthma Monitor AM3 G+" (510(k) K183479) is a Class II device cleared under 21 CFR 868.1840 (diagnostic spirometer), product code BZG, received 2019-09-03 and found substantially equivalent; its labeling is an electronic lung-function measurement device with a stored symptom/medication questionnaire function (up to 400 questionnaire sets, 20 questions each), for health-care, clinical, and home-use environments
jurisdiction: US — confidence: verified — source: openFDA device/classification product_code=BZG (Class 2, Spirometer Diagnostic, regulation 868.1840); openFDA device/510k k_number=K183479 (product code BZG, decision Substantially Equivalent); FDA 510(k) summary K183479…the full check (accessdata.fda.gov/cdrh_docs/pdf18/K183479.pdf), verbatim IFU confirms "electronic measurement device to monitor the lung function," children 5+, and the symptom/medications questionnaire (AMOS software) — note: decision date is actually 2019-10-03 per openFDA, not 2019-09-03 as claimed; the device_name on the FDA record is "Asthma Monitor AM3" (the "G+" model name appears inside the IFU text itself, not as the openFDA device_name field) — a minor naming/date correction, not a substantive miss.
claim 2unconfirmedUS
The "Safey Peak Flow Meter" (510(k) K200832) is a Class II, OTC, home-use peak-flow device indicated for children over 5 years of age, adolescents, and adults, with predicate device "Smart One" (K181666)
jurisdiction: US — confidence: unconfirmed — source: openFDA device/510k k_number=K200832 confirms the clearance is real (Safey Medical Devices Pvt, Ltd., decided 2020-07-30, product_code=BZH, decision=Substantially Equivalent — Class II follows from BZH's classification record, verified separately in claim 3);…the full check openFDA also confirms K181666 "Smart One" is a real BZH-coded 510(k) (Mir Medical International Research, decided 2018-08-01) — note: clearance-summary K200832 returned unconfirmed — FDA's PDF repository gives HTTP 401 for this K-number's summary at accessdata.fda.gov/cdrh_docs/pdf20/K200832.pdf, so the OTC-vs-Rx status, the "children over 5" age claim, and whether K200832's own filing actually cites K181666 as its predicate (rather than the two devices merely coexisting in the same product code) remain unconfirmed, not verified — this says nothing about whether those details are wrong, only that the primary document is unreachable from here.
claim 3verifiedUS
Peak-flow-meter-only 510(k) devices are commonly classified under 21 CFR 868.1860 with product code BZH
jurisdiction: US — confidence: verified — source: openFDA device/classification product_code=BZH: "Device class 2: Meter, Peak Flow, Spirometry (regulation 868.1860, review panel AN)"; corroborated by an openFDA clearances scan showing 12 distinct BZH-coded 510(k)s decided 2017-2024 (K200832, K230423, K203196,…the full check K181666, K180487 among them) — the third-party-URL-only sourcing flagged by the Generator is resolved; this is now a direct openFDA record.
claim 4unconfirmedUS
CPT code 99453 (remote physiologic monitoring, initial set-up and patient education) has a 2026 Medicare national non-facility reimbursement rate of approximately $21.71
jurisdiction: US — confidence: unconfirmed — source: python3 -m connectors payment 99453 returns unconfirmed — no local cache at data/hcpcs_payment_rates.csv (see data/README.md); no CMS Physician Fee Schedule data has been loaded into this repo for any of the three RPM codes. Not attempted as a hand-fetch:…the full check CMS's PFS national payment amounts require locality/GPCI-adjusted RVU computation from the raw RVU files, not a simple scrape, and a mis-transcribed cache file would be worse than none — this is a Scout task (fetch_data_file.py against a genuine CMS PFS release), not something to approximate here. This is the top Scorer-flagged priority claim and it remains unresolved.
claim 5unconfirmedUS
CPT code 99454 (remote physiologic monitoring, device supply with daily recording or programmed alert transmission, 16-30 days in a 30-day period) has a 2026 Medicare national non-facility reimbursement rate of approximately $47
jurisdiction: US — confidence: unconfirmed — source: python3 -m connectors payment 99454 returns unconfirmed for the same reason as claim 4 — no data/hcpcs_payment_rates.csv cache. Also checked python3 -m connectors coverage 99454: unconfirmed, no data/medicare_coverage_policies.csv cache — so beyond the rate…the full check being unresolved, no NCD/LCD naming this code for home pediatric RPM has been located or ruled out either.
claim 6unconfirmedUS
CPT code 99457 (remote physiologic monitoring treatment management, first 20 minutes) has a 2026 Medicare national non-facility reimbursement rate of approximately $52
jurisdiction: US — confidence: unconfirmed — source: python3 -m connectors payment 99457 returns unconfirmed for the same reason as claims 4-5 — no data/hcpcs_payment_rates.csv cache. python3 -m connectors coverage 99457 also unconfirmed, no coverage-policy cache. All three RPM CPT rate claims (4-6) are…the full check unresolved for the identical structural reason (missing local CMS cache, not a wrong number found) — flagging this as a Scout work item: populate data/hcpcs_payment_rates.csv and data/medicare_coverage_policies.csv from a real CMS release before this factor can move past "unconfirmed."
claim 7unconfirmedUS
TAM component 1 (population) — CDC data reported via web search states that approximately 4.8 million US children under 18 had "current asthma" in 2023, representing about 6.7% of the child population, with about 2.3 million of those children (47.1%) reporting an asthma attack in the prior year
jurisdiction: US — confidence: unconfirmed — source: no connector in this repo reaches CDC prevalence data; python3 -m connectors market "..." returns unverifiable by design for the same reason. procedures (Medicare FFS utilization) does not apply either — the target population is pediatric (ages 5-17),…the full check essentially outside Medicare FFS, so that connector's own coverage caveat (excludes non-Medicare populations) makes it the wrong instrument here, not a usable floor. This stays unconfirmed permanently absent a human-attached primary CDC/NHIS table; still flagged, as the Generator did, that the figure is all-severity "current asthma," not the persistent-asthma subgroup this candidate targets.
claim 8unconfirmedUS
TAM component 2 (price) — assuming monthly RPM billing per enrolled patient of one 99454 plus one 99457 unit (99453 is a one-time setup fee), the Generator computes an approximate recurring reimbursement of $99 per enrolled patient per month, before any practice overhead, billing-compliance cost, or non-payment/denial rate is netted out
jurisdiction: US — confidence: unconfirmed — source: python3 -m connectors market "..." returns unverifiable; this is Generator arithmetic built entirely on claims 5 and 6, both of which are themselves unconfirmed (missing CMS payment-rate cache, see claims 4-6) — the input rates were never independently confirmed,…the full check so this derived figure inherits that status unchanged, not resolved or worsened by this pass.
claim 9unconfirmedUS
TAM component 3 (addressable share) — the Generator assumes, without a primary source, that patients with physician-diagnosed persistent (mild, moderate, or severe persistent, as opposed to intermittent) asthma make up roughly 30-40% of the pediatric current-asthma population in claim 7, and that this subgroup is the plausible near-term prescribing target for RPM-billed monitoring
jurisdiction: US — confidence: unconfirmed — source: python3 -m connectors market "..." returns unverifiable; confirmed as an explicit unsourced estimate with no primary CDC/NHIS or clinical-registry breakout available through any connector in this repo.
claim 10verifiedUS
Multiple Class II connected/electronic peak-flow-meter and spirometer devices with pediatric (age 5+) home-use indications have received 510(k) clearance between 2018 and 2023, including K180487, K183479, K200832, K203196, and K230423
jurisdiction: US — confidence: verified — source: python3 -m connectors clearances --product-code BZG and --product-code BZH (2017-2024 window): confirms K180487 (2018-10-26, BZH), K183479 (2019-10-03, BZG), K200832 (2020-07-30, BZH), and K203196 (2021-05-26, BZH) are all real Class II clearances within the stated…the full check 2018-2023 window (21 CFR 868.1840/868.1860 both Class 2 per classification records above) — note: K230423 is also a real BZH clearance but its actual decision date is 2024-02-23, outside the claimed "2018 and 2023" range; that one citation's date is wrong, though it doesn't invalidate "multiple devices cleared 2018-2023" since four other named devices independently support it. No recall or adverse-event search was performed this pass either (this repo's recall connector was not run against these K-numbers) — that part of the claim's own caveat still stands unresolved.
claim 11unconfirmedUS
CMS's RPM billing rules require that the monitoring device meet FDA's regulatory definition of a medical device and that data be used in the management of a chronic or acute condition — a prescription-only, physician-ordered device positioned for chronic persistent-asthma management is intended to satisfy this requirement in a way that a general-wellness OTC peak-flow app would not
jurisdiction: US — confidence: unconfirmed — source: tried python3 -m connectors regulation 410.78/410.72/414.65 --title 42 (Medicare telehealth/MNT/telehealth-payment sections) looking for the RPM device-definition requirement; none contains it — all three are the wrong CFR sections for this specific requirement.…the full check The "device must meet FDA's definition of a medical device" language actually originates in CMS Physician Fee Schedule final-rule preambles (sub-regulatory guidance), not a codified CFR provision this connector's scope covers — same limitation documented for FDA guidance: interpretation of how CMS applies a rule is out of reach here. Remains an unsourced design assumption, as the Generator itself flagged; a Federal Register policy lookup against the specific PFS final-rule document number (not identified here) would be the next step, not a regulation-text search.
claim 12unconfirmedUS
No freedom-to-operate or patent search was performed by the Generator for the peak-flow/spirometer hardware, the connected symptom-tracking questionnaire function, or any exacerbation-risk-flagging logic; predicate hardware in this space (electronic peak-flow meters, digital spirometers) has been on the market since at least the mid-2010s, but FTO for the specific combination of continuous RPM billing plus an action-plan-threshold alerting algorithm is entirely unexamined
jurisdiction: US — confidence: unconfirmed — source: python3 -m connectors patent <id> requires a specific patent number to check and there is none named in this claim to run it against (it is, by design, a keyword-less, ID-only lookup — no FTO landscape search exists in this repo); also…the full checkEPO_OPS_KEY/EPO_OPS_SECRET are unset in this environment regardless, so even a spot-check on a candidate patent would return unconfirmed. This claim remains exactly what it says it is: FTO for this specific hardware+billing+alerting combination is genuinely unexamined, not merely unconfirmed by omission — flagged for the Scorer/Scout as an open gate-relevant risk (FTO/IP is one of the four core factors the Stage 5 gate depends on), not a cleared factor.
claim 13unconfirmedUS
Assumption, not a fact: the idea depends on prescribing physicians (pediatricians, pediatric pulmonologists, allergists) being willing to order home RPM monitoring for persistent pediatric asthma and to bill for the associated CPT codes at a rate sufficient to justify a dedicated device, rather than treating in-office spirometry and periodic action-plan review as sufficient. There is no connector for clinician prescribing behavior and no primary research cited here supporting this belief; it is stated explicitly as an assumption rather than a fact so it stays visible to the Scorer and Verifier
jurisdiction: US — confidence: unconfirmed — source: python3 -m connectors adoption "..." returns unverifiable, as it always does for stakeholder-preference claims; no model judgment was substituted. Confirmed this remains an unsourced assumption, not evaluated further.
claim 14unconfirmedUS
Assumption, not a fact: the idea depends on parents/guardians and school-age children being willing to perform a daily home peak-flow/spirometry maneuver and complete a symptom questionnaire with enough consistency to produce clinically useful RPM data (RPM billing under 99454 requires at least 16 days of readings in a 30-day period). No primary adherence data for this population and device concept is cited here; stated explicitly as an assumption
jurisdiction: US — confidence: unconfirmed — source: python3 -m connectors adoption "..." returns unverifiable, as it always does for stakeholder-preference claims; no model judgment was substituted. Confirmed this remains an unsourced assumption, not evaluated further.
claim 15verifiedUS
CMS's own Remote Patient Monitoring coverage page states patient eligibility requires a chronic OR acute condition that requires monitoring, and an internet-connected device that meets FDA's definition of a medical device, digitally uploads data, and collects/transmits health data at least 2 days every 30 days
jurisdiction: US — confidence: verified — source: cms.gov/medicare/coverage/telehealth/remote-patient-monitoring, fetched directly this pass (no dedicated connector for CMS coverage-topic pages exists in this repo, so this was a direct primary-source read, not a connectors call) — page text confirms verbatim: "Have…the full check a chronic or acute condition that requires monitoring" / "Use an internet-connected device that: [o] Meets that FDA's definition of a medical device and digitally uploads data [o] Collects and transmits health data at least 2 days every 30 days"; page's own "Page Last Modified" field reads "05/13/2026", matching the claimed 2026-05-13 date exactly.
claim 16verifiedUS
CMS's CY2026 Physician Fee Schedule National Payment Amount File (revision PFREV26A) lists non-facility payment amounts for CPT 99453 ranging from $18.42 to $30.70 across the 109 Medicare payment localities (mean $22.53, median $22.18)
jurisdiction: US — confidence: verified — source: python3 -m connectors payment 99453 still returns unconfirmed (no local data/hcpcs_payment_rates.csv cache exists in this repo — a Scout task, not a finding of a wrong number) so this claim was checked directly against the primary document instead: fetched…the full checkhttps://www.cms.gov/files/zip/pfrev26a-updated-12-29-2025.zip (confirmed live, HTTP 200, content-type application/zip, CMS host, last-modified 2025-12-29), unzipped to PFALL26AR.txt (the file the record-layout PDF PF26PAR.pdf inside the same archive names as "PFALL26A.TXT...containing the applicable physician fee schedule pricing information"), and parsed the 109 carrier/locality rows for HCPCS 99453 (non-facility fee schedule amount field, columns 35-44 per the layout PDF) — computed min $18.42, max $30.70, mean $22.53, median $22.18, exactly matching the claim's figures.
claim 17verifiedUS
The same CMS file lists non-facility payment amounts for CPT 99454 ranging from $44.64 to $74.83 across the 109 Medicare payment localities (mean $54.32, median $53.00)
jurisdiction: US — confidence: verified — source: same direct fetch and parse of PFALL26AR.txt from PFREV26A as claim 16 (connector payment 99454 still unconfirmed, no local cache) — computed for HCPCS 99454's non-facility fee schedule amount across all 109 rows: min $44.64, max $74.83, mean $54.32, median $53.00…the full check — exact match.
claim 18verifiedUS
The same CMS file lists non-facility payment amounts for CPT 99457 ranging from $46.88 to $66.68 across the 109 Medicare payment localities (mean $53.31, median $52.58); the same code's facility-setting amounts are materially lower, $25.08 to $36.28 (mean $26.81)
jurisdiction: US — confidence: verified — source: same direct fetch and parse of PFALL26AR.txt from PFREV26A as claims 16-17 (connector payment 99457 still unconfirmed, no local cache) — computed for HCPCS 99457 across all 109 rows: non-facility fee schedule amount min $46.88, max $66.68, mean $53.31, median…the full check $52.58; facility fee schedule amount min $25.08, max $36.28, mean $26.81 — exact match on every figure. Note: data/hcpcs_payment_rates.csv still does not exist, so the payment connector itself remains unconfirmed for all three RPM codes — this verification bypassed that gap by reading CMS's own file directly, but the repo's cache-backed tooling is still a genuine Scout gap worth closing.
claim 19verifiedUS
A Philips-sponsored pediatric home-asthma-RPM eHealth study (ALPACA, ages 4-11, moderate-to-severe asthma) was withdrawn before enrolling any participants; ClinicalTrials.gov records the sponsor's stated reason as 'refocus of business'
jurisdiction: US — confidence: verified — source: python3 -m connectors trial-detail NCT05517096 — confirms title "AmbuLatory Pediatric Asthma CAre" (ALPACA), sponsor "Philips Electronics Nederland B.V. acting through Philips CTO organization" (INDUSTRY), status=WITHDRAWN, enrollment 0 (ACTUAL), population ages 4…the full check Years-11 Years, eligibility "Children with moderate-to-severe asthma," whyStopped (verbatim) "refocus of business" — every element of the claim matches the ClinicalTrials.gov record exactly.
claim 20verifiedUS
A Weill Cornell-sponsored pilot of remote asthma-medication monitoring for pediatric patients with persistent asthma (ages 3-21) was terminated after enrolling 12 of its intended participants; ClinicalTrials.gov records the stated reason as 'Staffing issues with partner site'
jurisdiction: US — confidence: verified — source: python3 -m connectors trial-detail NCT05139485 — confirms title "Evaluation of a Remote Asthma Monitoring Program to Improve Health Outcomes in Pediatric Asthma," sponsor "Weill Medical College of Cornell University" (OTHER), status=TERMINATED, enrollment 12…the full check (ACTUAL), population ages 3 Years-21 Years, eligibility "Diagnosis of persistent asthma (mild, moderate, severe)," whyStopped (verbatim) "Staffing issues with partner site." — note: the record's ACTUAL-enrollment field (12) matches the claim; the record itself does not separately expose a distinct "intended"/target-enrollment number for this connector to confirm 12 fell short of a larger target, but a TERMINATED status with an ACTUAL count is standard ClinicalTrials.gov shorthand for exactly that, and every other detail matches verbatim.
claim 21verifiedUS
FDA product codes BZG (diagnostic spirometer, 21 CFR 868.1840) and BZH (peak-flow meter, 21 CFR 868.1860) show 24 and 14 distinct 510(k) clearances respectively in the 2016-2026 window, spanning well over a dozen distinct applicants beyond the 4-5 devices previously identified for this candidate
jurisdiction: US — confidence: verified — source: python3 -m connectors clearances --product-code BZG --since 2016-09-02 --until 2026-08-31 --limit 100 returns count=24, total_matches=24, not truncated; --product-code BZH (same window) returns count=14, total_matches=14, not truncated — exact match on both counts.…the full check Applicant names parsed from the returned record titles show 30 distinct-or-near-distinct manufacturer names across the combined BZG+BZH set (a few pairs are the same company under slightly different legal-entity names, e.g. "Mir Medical International Research" vs "...USA"), comfortably supporting "well over a dozen distinct applicants."
claim 22verifiedUS
Among US children with current asthma, an estimated 60.3% have persistent-severity asthma and 39.7% have intermittent-severity asthma, per CDC's classification of BRFSS Adult Asthma Call-back Survey data covering 35 states plus DC, 2006-2010
jurisdiction: US — confidence: verified — source: cold re-retrieval of archive.cdc.gov/www_cdc_gov/asthma/asthma_stats/severity_child.htm this pass (no connector reaches CDC archive pages; direct primary-source fetch) — page's own state-level table gives the row "U.S. Total ** 39.7 60.3" under columns "Intermittent…the full check Severity%" / "Persistent Severity%", and the footnote reads "U.S. Total includes participating states (n=35) plus District of Columbia and excludes the three U.S. territories," sourced to "Behavioral Risk Factors Surveillance System (BRFSS)—Adult Asthma Call-back survey Data, 2006-2010" — every figure and detail matches exactly.
claim 23verifiedUS
Current asthma prevalence among US children differed sharply by race in 2010-2021 NHIS data: 12.5% among non-Hispanic Black children (adjusted prevalence ratio 2.19, 95% CI 1.68-2.84) versus 5.7% among non-Hispanic White children
jurisdiction: US — confidence: verified — source: python3 -m connectors literature-detail 39025120 — "The Status of Asthma in the United States" (Preventing Chronic Disease, 2024), structured abstract confirms verbatim: "Prevalence of current asthma was higher among non-Hispanic Black people (children, 12.5%;…the full check adjusted prevalence ratio [APR] = 2.19; 95% CI, 1.68-2.84... compared with non-Hispanic White people (children, 5.7%...)"; methods section confirms use of "2010-2021 National Health Interview Survey (NHIS)" — exact match on every figure.
claim 24verifiedUS
An app-based portable home spirometer (VitalFlo) measuring FEV1 correlated highly with a clinic-grade spirometer (nSpire KoKo sx1000) in a validation study of 48 adolescents with persistent asthma (240 total pulmonary-function measurements), with no statistically significant difference in mean FEV1 between devices (mean difference 0.00764 L, P=.87)
jurisdiction: US — confidence: verified — source: python3 -m connectors literature-detail 31810411 — "Validation of an app-based portable spirometer in adolescents with asthma" (Journal of Asthma, 2021), structured abstract confirms verbatim: "Two hundred forty pulmonary function measurements were collected from 48…the full check adolescents with persistent asthma," compared VitalFlo to "nSpire KoKo® sx1000," and "There were no statistically significant differences of the mean FEV1 (M = 0.00764, SD = 0.364, t(59)=0.16, P = 0.87)... between the VitalFlo and nSpireKoKo® systems" — exact match on every figure.
claim 25verifiedUS
Children and adolescents with treated asthma incurred $3,362.56 in additional annual medical expenditures compared with those without treated asthma, in a cross-sectional analysis of 2,365 children with treated asthma versus 40,497 without, using 2016-2021 Medical Expenditure Panel Survey data
jurisdiction: US — confidence: verified — source: python3 -m connectors literature-detail 39052508 — "Sociodemographic Factors of Asthma Prevalence and Costs Among Children and Adolescents in the United States, 2016-2021" (Preventing Chronic Disease, 2024), structured abstract confirms verbatim: "a cross-sectional…the full check study of 2,365 children and adolescents (aged 0-17 y) with treated asthma compared with 40,497 children and adolescents without treated asthma," using "2016-2021 Medical Expenditures Panel Survey" data, and "Children and adolescents with treated asthma had $3,362.56 in additional annual medical expenditures... compared with children and adolescents without treated asthma" — exact match on every figure.
claim 26unverifiedUS
Families of children prescribed this device will be able and willing to pay the out-of-pocket cost (copay, coinsurance, or device cost) that remains after insurance reimburses the CPT 99453/99454/99457 RPM charges.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (desirability deck, 2026-09-01) — never checked; recorded so the Verifier can see it
claim 27unverifiedUS
Enrolling a pediatric persistent-asthma patient in this home RPM peak-flow/spirometry-and-symptom-tracking program reduces asthma exacerbations, emergency-department visits, or hospitalizations relative to standard in-office spirometry and periodic action-plan review.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (desirability deck, 2026-09-01) — never checked; recorded so the Verifier can see it
claim 28unverifiedUS
A state Medicaid program or commercial health plan reimburses CPT 99453/99454/99457 for pediatric remote physiologic monitoring at rates comparable to the CY2026 Medicare non-facility Physician Fee Schedule payment amounts.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (viability deck, 2026-09-01) — never checked; recorded so the Verifier can see it
claim 29unverifiedUS
This candidate's own hardware (not the VitalFlo analog) achieves FEV1/peak-expiratory-flow measurement accuracy, relative to clinic-grade spirometry, comparable to what VitalFlo demonstrated in adolescents with persistent asthma, when tested in the candidate's own 5-17 target age range.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (feasibility deck, 2026-09-01) — never checked; recorded so the Verifier can see it
claim 30unverifiedUS
The threshold-based alerting algorithm that flags out-of-range readings against a patient-specific asthma action-plan threshold achieves clinically acceptable sensitivity and specificity for detecting exacerbation risk in pediatric persistent-asthma patients.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (feasibility deck, 2026-09-01) — never checked; recorded so the Verifier can see it
claim 31unverifiedUS
The app's data pathway from the home device into the prescribing clinician's RPM/EHR workflow meets FDA's applicable cybersecurity and software-documentation requirements for this device's regulatory class.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (feasibility deck, 2026-09-01) — never checked; recorded so the Verifier can see it
claim 32unverifiedUS
The 2023 CDC-reported pediatric 'current asthma' population figure (approximately 4.8 million US children) and the 2006-2010 BRFSS-derived 60.3% persistent-severity share are commensurable enough to multiply into a current addressable persistent-pediatric-asthma population estimate, despite the roughly 15-17 year gap between the two surveys.
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-03) — never checked; recorded so the Verifier can see it
claim 33unverifiedUS
A pediatric prescribing practice (pediatrics, pediatric pulmonology, or allergy) would pay a device acquisition or lease price for this RPM-eligible peak-flow/spirometry monitor high enough to support a standalone device business at achievable enrollment volumes.
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-03) — never checked; recorded so the Verifier can see it
claim 34unverifiedUS
A material share of the US addressable persistent-pediatric-asthma population is currently enrolled by any prescriber into RPM billing for any connected home-monitoring device, independent of which specific device is used.
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-03) — never checked; recorded so the Verifier can see it
claim 35unverifiedUS
This candidate's specific device captures a defined, non-trivial share of RPM-enrolled persistent-pediatric-asthma patients by year 3, rather than one of the approximately 38 already-cleared competing connected peak-flow-meter or spirometer devices in product codes BZG and BZH.
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-03) — never checked; recorded so the Verifier can see it
claim 36unverifiedUS
A prescribing practice's fully-loaded cost to run this RPM program for one enrolled patient -- device supply, clinician/staff time reviewing data, and billing-compliance overhead -- is below the CY2026 CMS non-facility reimbursement for that patient, leaving a margin worth pursuing.
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-03) — never checked; recorded so the Verifier can see it
claim 37unverifiedUS
Gross margin on the device itself, at an acquisition price a prescribing practice would actually pay, supports a standalone device business.
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-03) — never checked; recorded so the Verifier can see it
claim 38unverifiedUS
The lag between a patient's first enrollment in this RPM program and the practice's first paid RPM claim -- payer enrollment, prior authorization, and the 30-day data-collection window CPT 99454 itself requires -- is short enough to finance without additional working capital.
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-03) — never checked; recorded so the Verifier can see it
claim 39unverifiedUS
Calendar time from today to FDA clearance, under whichever of the two candidate-identified 510(k) routes actually governs this device, is on the order of months rather than years.
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-03) — never checked; recorded so the Verifier can see it
claim 40unverifiedUS
Capital required to reach FDA clearance under whichever 510(k) route governs, plus a first commercial device sale to a prescribing practice, is within a typical Class II device-startup budget.
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-03) — never checked; recorded so the Verifier can see it